Gorman C. Kevin's Insider Trades & SAST Disclosures
Gorman C. Kevin's most recent trade in Neurocrine Biosciences, Inc. was a trade of 5,603 Restricted Stock Unit done . Disclosure was reported to the exchange on Feb. 13, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Gorman C. Kevin.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 5,603 | 16,812 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 5,603 | 527,221 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 5,376 | 10,754 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 5,376 | 524,450 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director | Sale of securities on an exchange or to another person at price $ 116.68 per share. | 13 Feb 2025 | 3,012 | 524,209 (0%) | 0% | 116.7 | 351,450 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director | Sale of securities on an exchange or to another person at price $ 116.69 per share. | 13 Feb 2025 | 2,832 | 521,618 (0%) | 0% | 116.7 | 330,465 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2025 | 4,318 | 521,348 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2025 | 4,318 | 0 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director | Sale of securities on an exchange or to another person at price $ 118.37 per share. | 08 Feb 2025 | 2,274 | 519,074 (0%) | 0% | 118.4 | 269,167 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 5,141 | 519,737 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 5,141 | 5,142 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director | Sale of securities on an exchange or to another person at price $ 152.92 per share. | 31 Jan 2025 | 2,707 | 517,030 (0%) | 0% | 152.9 | 413,967 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.99 per share. | 27 Jan 2025 | 146,105 | 660,701 (0%) | 0% | 33.0 | 4,820,004 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director | Sale of securities on an exchange or to another person at price $ 149.46 per share. | 27 Jan 2025 | 146,105 | 514,596 (0%) | 0% | 149.5 | 21,836,503 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2025 | 146,105 | 0 | - | - | Non-Qualified Stock Option | |
| Xencor Inc | Kevin C. Gorman | Director | Sale of securities on an exchange or to another person at price $ 20.68 per share. | 27 Sep 2024 | 2,654 | 8,392 (0%) | 0% | 20.7 | 54,885 | Common Stock |
| Xencor Inc | Kevin C. Gorman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 11,971 | 11,971 | - | - | Stock Option (Right to Buy) | |
| Xencor Inc | Kevin C. Gorman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 5,986 | 11,046 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Kevin Gorman C. | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 112,644 | 112,644 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | C. Kevin Gorman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 22,415 | 22,415 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Gorman C. Kevin | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 133.02 per share. | 13 Feb 2024 | 2,832 | 514,596 (0%) | 0% | 133.0 | 376,700 | Common Stock |
| Neurocrine Biosciences, Inc. | C. Gorman Kevin | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 35.99 per share. | 13 Feb 2024 | 2,778 | 509,740 (0%) | 0% | 36.0 | 99,980 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin Gorman C. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 2,778 | 0 | - | - | Incentive Stock Option | |
| Neurocrine Biosciences, Inc. | Gorman Kevin C. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.24 per share. | 13 Feb 2024 | 2,312 | 512,052 (0%) | 0% | 43.2 | 99,971 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin Gorman C. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 2,312 | 0 | - | - | Incentive Stock Option | |
| Xencor Inc | Gorman C. Kevin | Director | Purchase of securities on an exchange or from another person at price $ 19.11 per share. | 13 Feb 2024 | 53 | 5,060 (0%) | 0% | 19.1 | 1,013 | Common Stock |
| Neurocrine Biosciences, Inc. | Gorman Kevin C. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 142.18 per share. | 06 Feb 2024 | 3,040 | 504,919 (0%) | 0% | 142.2 | 432,218 | Common Stock |
| Neurocrine Biosciences, Inc. | C. Kevin Gorman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 134.15 per share. | 06 Feb 2024 | 2,274 | 506,962 (0%) | 0% | 134.1 | 305,052 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin Gorman C. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 140.69 per share. | 31 Jan 2024 | 2,707 | 502,188 (0%) | 0% | 140.7 | 380,845 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin Gorman C. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2024 | 105,835 | 62,023 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.59 per share. | 08 Jan 2024 | 105,835 | 605,589 (0%) | 0% | 19.6 | 2,073,308 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin Gorman C. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 132.44 per share. | 08 Jan 2024 | 105,835 | 499,754 (0%) | 0% | 132.4 | 14,016,523 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin Gorman C. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.59 per share. | 08 Jan 2024 | 62,023 | 561,777 (0%) | 0% | 19.6 | 1,215,031 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin Gorman C. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 134.01 per share. | 08 Jan 2024 | 62,023 | 499,754 (0%) | 0% | 134.0 | 8,311,895 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin Gorman C. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2024 | 62,023 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 107.40 per share. | 21 Aug 2023 | 9,328 | 499,754 (0%) | 0% | 107.4 | 1,001,816 | Common Stock |
| Xencor Inc | Kevin C. Gorman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 10,013 | 10,013 | - | - | Stock Option (Right to Buy) | |
| Xencor Inc | Kevin C. Gorman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 5,007 | 5,007 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 133,656 | 133,656 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 21,506 | 21,506 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 102.43 per share. | 06 Feb 2023 | 20,482 | 489,322 (0%) | 0% | 102.4 | 2,098,049 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 102.30 per share. | 06 Feb 2023 | 3,248 | 470,930 (0%) | 0% | 102.3 | 332,266 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 105.68 per share. | 06 Feb 2023 | 3,040 | 468,008 (0%) | 0% | 105.7 | 321,259 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 104.30 per share. | 06 Feb 2023 | 2,274 | 491,365 (0%) | 0% | 104.3 | 237,185 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 110.08 per share. | 31 Jan 2023 | 2,707 | 465,278 (0%) | 0% | 110.1 | 297,997 | Common Stock |
| Xencor Inc | Kevin C. Gorman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 21,412 | 21,412 | - | - | Stock Option (Right to Buy) | |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 80.82 per share. | 07 Feb 2022 | 3,248 | 458,071 (0%) | 0% | 80.8 | 262,518 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 80.80 per share. | 07 Feb 2022 | 3,040 | 460,801 (0%) | 0% | 80.8 | 245,630 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 80.83 per share. | 07 Feb 2022 | 2,422 | 455,150 (0%) | 0% | 80.8 | 195,759 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 79.49 per share. | 07 Feb 2022 | 2,274 | 462,844 (0%) | 0% | 79.5 | 180,768 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 140,049 | 140,049 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 20,565 | 20,565 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 113,863 | 113,863 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2021 | 164,801 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 110.22 per share. | 08 Jan 2021 | 164,801 | 441,071 (0%) | 0% | 110.2 | 18,164,778 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.65 per share. | 08 Jan 2021 | 164,801 | 605,872 (0%) | 0% | 8.7 | 1,425,529 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2021 | 143,449 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 110.21 per share. | 08 Jan 2021 | 143,449 | 441,071 (0%) | 0% | 110.2 | 15,809,098 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.66 per share. | 08 Jan 2021 | 143,449 | 584,520 (0%) | 0% | 8.7 | 1,242,268 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 90.78 per share. | 12 Nov 2020 | 3,390 | 441,071 (0%) | 0% | 90.8 | 307,748 | Common Stock |
| Neurocrine Biosciences, Inc. | Kevin C. Gorman | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 118.91 per share. | 05 Aug 2020 | 3,390 | 438,021 (0%) | 0% | 118.9 | 403,101 | Common Stock |
| Xencor Inc | Kevin C. Gorman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 13,953 | 13,953 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges